Skip to main content

Veno-venous extracorporeal CO2 removal for the treatment of severe respiratory acidosis

We read with interest the article by Karagiannidis and colleagues reporting the effects of extracorporeal CO2 removal (ECCO2R) in a pig model of severe respiratory acidosis [1]. However, their conclusion that blood flow rates between 750 and 1,000 ml/minute are necessary to correct severe acidosis using ECCO2R may have been biased by limitations in experimental methodology.

Firstly, the authors report CO2 removal rates for various blood flow rates using 19Fr and 14Fr catheters. However, the data clearly demonstrated blood recirculation using the 14Fr catheter, reducing CO2 removal efficiency. Although the authors mention this limitation, it is curious why the 14Fr data were presented at all, since recirculation confounds meaningful interpretation.

Secondly, a 15-minute equilibration time was used between experimental set points, but no evidence is provided that equilibrium was achieved. It is reasonable to expect equilibration within 15 minutes when the entire cardiac output participates in gas exchange, but in this study blood flow rates of only 200 to 1,000 ml/minute passed through the gas exchanger. Longer equilibration times may have resulted in continued pH correction, as demonstrated in a human ECCO2R pilot study using approximately 450 ml/minute blood flows [2].

Finally, this study demonstrates reductions of partial pressure of CO2 from 107.9 to 76.9 mmHg with blood flows of 500 ml/minute. In clinical practice this may be sufficient, a reduction from 80-85 to 60-65 mmHg in chronic obstructive pulmonary disease patients with respiratory acidosis normalized pH, allowing intubation to be avoided [2].

Although ECCO2R with higher blood flows clearly increases CO2 removal, lower flows with appropriately designed catheters may provide sufficient support for severe hypercapnic respiratory failure.

Author response

We are grateful for the comments to our recent manuscript [1] provided by Cove and Federspiel and we very much appreciate their effort in further elucidating the concept of ECCO2R. We are happy to respond to their comments as follows.

Cove and Federspiel are correct in stating that ECCO2R was insufficient using 14.5Fr catheters and that this was also attributable to recirculation. It was one of the intentions of our study to explicitly show this [1]. However, ECCO2R was insufficient in our experimental setting, too, when using 19Fr catheters at blood flow rates of 500 ml/minute while recirculation was negligible. This indicates that lower blood rates per se contributed to insufficient ECCO2R.

We agree that equilibrium for CO2 may not have been completed after 15 minutes, because bicarbonate is stored in slow compartments. However, in addition to the information already given in the methods section we observed that CO2 measures at the exhaust outlet were very stable after 15 minutes, supporting the assumption that equilibrium for CO2 was largely achieved.

Finally, we acknowledge the existing, albeit small scientific evidence for the clinical application of ECCO2R in patients. The patients in the study mentioned were far less acidotic, were mostly breathing spontaneously and were in a fairly stable condition [2]. Therefore, the results of our study setting with severely acidotic pigs are not transferrable to these conditions. To normalize severe respiratory acidosis, blood flows in the range of 750 to 1,000 ml/minute are necessary; less may be sufficient to avoid intubation in non-invasive ventilation failure under certain conditions.

Abbreviations

ECCO2R:

Extracorporeal CO2 removal

References

  1. Karagiannidis C, Kampe KA, Sipmann FS, Larsson A, Hedenstierna G, Windisch W, et al. Veno-venous extracorporeal CO2 removal for the treatment of severe respiratory acidosis: pathophysiological and technical considerations. Crit Care. 2014;18:R124.

    Article  Google Scholar 

  2. Burki NK, Mani RK, Herth FJ, Schmidt W, Teschler H, Bonin F, et al. A novel extracorporeal CO(2) removal system: results of a pilot study of hypercapnic respiratory failure in patients with COPD. Chest. 2013;143:678–86.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by new clinician scientist program (MEC) and NMRC TA grant NMRC/TA/0015/2013 (MEC).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Matthew E Cove.

Additional information

Competing interests

MEC has no competing interests to declare. WJF is head of the scientific advisory board at ALung Technologies, and has an equity interest in this company. CK received travel grants and lecture fees from Maquet, Rastatt, Germany. WW received fees for advisory board meetings and lectures from Maquet, Rastatt, Germany. TM received travel grants from Maquet, Rastatt, Germany.

See related research by Karagiannidis et al. http://ccforum.com/content/18/3/R124

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cove, M.E., Federspiel, W.J. Veno-venous extracorporeal CO2 removal for the treatment of severe respiratory acidosis. Crit Care 19, 176 (2015). https://doi.org/10.1186/s13054-015-0769-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13054-015-0769-0

Keywords